COL1A1 and cancer: In the era of precision medicine, it would be exciting to carry out a biomarker-guided basket trial to study the potential role of COL1A1 inhibitors in different cancers, and it might be an optional treatment for patients with advanced tumors, just like pembrolizumab could be used in MSI-H patients.